Business Description
JCR Pharmaceuticals Co Ltd
ISIN : JP3701000006
Share Class Description:
JCRRF: Ordinary SharesTotal Employee Number:
987Description
JCR Pharmaceuticals Co Ltd is a drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth plan. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements. It operates in a single segment which is Pharmaceutical Business.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.18 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 1.25 | |||||
Debt-to-EBITDA | 10.96 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.53 | |||||
Beneish M-Score | -2.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.3 | |||||
3-Year EBITDA Growth Rate | -20.8 | |||||
3-Year EPS without NRI Growth Rate | -47.2 | |||||
3-Year FCF Growth Rate | 5.1 | |||||
3-Year Book Growth Rate | -2.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 99.6 | |||||
9-Day RSI | 80.41 | |||||
14-Day RSI | 52.26 | |||||
3-1 Month Momentum % | -20.62 | |||||
6-1 Month Momentum % | -20.62 | |||||
12-1 Month Momentum % | -33.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.09 | |||||
Quick Ratio | 0.59 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 870.25 | |||||
Days Sales Outstanding | 126.19 | |||||
Days Payable | 35.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.75 | |||||
Dividend Payout Ratio | 3.73 | |||||
Forward Dividend Yield % | 3.83 | |||||
5-Year Yield-on-Cost % | 3.44 | |||||
3-Year Average Share Buyback Ratio | 0.7 | |||||
Shareholder Yield % | -17.34 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.81 | |||||
Operating Margin % | -2.27 | |||||
Net Margin % | 2.03 | |||||
EBITDA Margin % | 11.88 | |||||
FCF Margin % | -27.62 | |||||
OCF Margin % | -0.32 | |||||
ROE % | 1.82 | |||||
ROA % | 0.77 | |||||
ROIC % | -0.43 | |||||
3-Year ROIIC % | -16.43 | |||||
ROC (Joel Greenblatt) % | 3.52 | |||||
ROCE % | 3.91 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 63.85 | |||||
Forward PE Ratio | 174.74 | |||||
Shiller PE Ratio | 13.28 | |||||
PS Ratio | 1.41 | |||||
PB Ratio | 1.36 | |||||
Price-to-Tangible-Book | 1.44 | |||||
EV-to-EBIT | 39.69 | |||||
EV-to-Forward-EBIT | 18.05 | |||||
EV-to-EBITDA | 19.87 | |||||
EV-to-Forward-EBITDA | 14.61 | |||||
EV-to-Revenue | 2.48 | |||||
EV-to-Forward-Revenue | 3.82 | |||||
EV-to-FCF | -8.96 | |||||
Price-to-GF-Value | 0.58 | |||||
Price-to-Median-PS-Value | 0.27 | |||||
Earnings Yield (Greenblatt) % | 2.52 | |||||
FCF Yield % | -19.52 | |||||
Forward Rate of Return (Yacktman) % | 12.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:JCRRF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JCR Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 267.325 | ||
| EPS (TTM) ($) | 0.052 | ||
| Beta | 0.1554 | ||
| 3-Year Sharpe Ratio | -0.76 | ||
| 3-Year Sortino Ratio | -0.87 | ||
| Volatility % | 32.41 | ||
| 14-Day RSI | 52.26 | ||
| 14-Day ATR ($) | 0.004715 | ||
| 20-Day SMA ($) | 3.3115 | ||
| 12-1 Month Momentum % | -33.8 | ||
| 52-Week Range ($) | 3.145 - 5 | ||
| Shares Outstanding (Mil) | 122.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JCR Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JCR Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| JPY 10.000000 Cash Dividend | 2026-09-30 | In 53 days | ||
| JPY 10.000000 Cash Dividend | 2026-03-31 | 4.17 (+0.00%) | ||
| JPY 10.000000 Cash Dividend | 2026-03-30 | 4.17 (+0.00%) | ||
| JPY 10.000000 Cash Dividend | 2025-09-29 | 4.25 (+0.00%) | ||
| JPY 10.000000 Cash Dividend | 2025-03-28 | 4.57 (+0.00%) | ||
| JPY 10.000000 Cash Dividend | 2024-09-27 | 4.70 (+0.00%) | ||
| 4:1 Stock Split | 2020-09-29 | -- |
Show
Entries
JCR Pharmaceuticals Co Ltd Frequently Asked Questions
What is JCR Pharmaceuticals Co Ltd(JCRRF)'s stock price today?
The current price of JCRRF is $3.32. The 52 week high of JCRRF is $5.00 and 52 week low is $3.15.
When is next earnings date of JCR Pharmaceuticals Co Ltd(JCRRF)?
The next earnings date of JCR Pharmaceuticals Co Ltd(JCRRF) is .
Does JCR Pharmaceuticals Co Ltd(JCRRF) pay dividends? If so, how much?
The Dividend Yield %  of JCR Pharmaceuticals Co Ltd(JCRRF) is 3.75% (As of Today), Highest Dividend Payout Ratio of JCR Pharmaceuticals Co Ltd(JCRRF) was 4.5. The lowest was 0.16. And the median was 0.39. The  Forward Dividend Yield % of JCR Pharmaceuticals Co Ltd(JCRRF) is 3.83%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on OTCPK:JCRRF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc. | 2020-04-27 |
Articles on JCR Pharmaceuticals Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers